GlassScriptPhysician profile
Michael W Savelle
NPI 1568078483
$5,072.38
in general payments reported to CMS, 2019-2025
29 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $685 · 2022: $875 · 2023: $1,123 · 2024: $1,350 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,512.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $929.48 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $776.08 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $655.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $410.61 | 2021-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $328.53 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.64 | 2021-2025 | Jardiance |
| Pfizer INC. | $261.88 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $225.96 | 2022-2024 | |
| Amarin Pharma, INC. | $221.85 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $194.63 | 2023-2024 | Rexulti |
| Paratek Pharmaceuticals, INC. | $123.38 | 2021-2025 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $91.97 | 2024 | |
| Kyowa Kirin, INC. | $60.37 | 2024 | Crysvita |
| Horizon Therapeutics Plc | $58.56 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $58.21 | 2022-2023 | Livalo, Seglentis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $50.99 | 2021-2024 | Xyosted |
| Glaxosmithkline, LLC. | $44.28 | 2022 | |
| Sumitomo Pharma America, INC. | $40.70 | 2025 | Gemtesa |
| Ibsa Pharma INC. | $36.40 | 2022 | |
| Ucb, INC. | $26.78 | 2023 | Nayzilam |
| Takeda Pharmaceuticals U.S.A., INC. | $22.58 | 2025 | Trintellix |
| Insulet Corporation | $21.91 | 2024 | Omnipod |
| Allergan, INC. | $21.72 | 2021 | |
| Alkermes, INC. | $17.06 | 2024 | Aristada, Lybalvi |
| Exact Sciences Corporation | $16.19 | 2025 | The Cologuard Plus Collection Kit |
| Mannkind Corporation | $14.14 | 2023 | Afrezza |
| Scilex Pharmaceuticals INC. | $13.64 | 2021 | |
| Merck Sharp & Dohme LLC | $13.29 | 2023 | Verquvo, Steglatro, Belsomra |
| Genentech USA, INC. | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Savelle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.